U.S. Degenerative Disc Disease Treatment Market to Exceed 3.9M Patients

According to Coherent Market Insights, the U.S. degenerative disc disease treatment market is estimated to have 2.644 million patients suffering from DDD in 2021 and is expected to exhibit a compound annual growth rate (CAGR) of 5.9 percent during the forecast period (2021-2028).
 
Key trends in the market include robust product pipeline for the treatment of degenerative disc disease which are estimated to launch during the forecast period is expected to drive the growth of the U.S. degenerative disc disease treatment market over the forecast period. In June 2018, University of Minnesota initiated a phase III clinical trial study of combination drugs which include morphine, epinephrine, and naropin for the treatment of patients suffering from lumbar disc herniation, degenerative disc disease, and spondylolisthesis. The study is estimated to complete by September 2021.
 
Furthermore, in August 2020, University of Iowa initiated a phase II clinical trial study of tranexamic Acid (TXA) in lumbar interbody spinal fusion, a condition of degenerative disc disease. The study is estimated to be completed by August 2022.
 
Key players operating in the market are focusing on development and launch of novel therapeutics for the treatment of degenerative disc disease which is expected to drive the market growth over the forecast period. In October 2019, Creative Medical Technology Holdings Inc., a biotechnology company, launched StemSpine, a patented procedure for the treatment of chronic lower back pain (CLBP) in the United States after successful treatments overseas with 12-plus month’s data showing safety and efficacy.
 
On the basis of treatment, narcotics segment is estimated to hold a dominant position in the U.S. degenerative disc disease treatment market due to increasing research and development activities for the development of novel narcotics treatment for the patients suffering from degenerative disc disease is expected to drive the segment growth over the forecast period. 
 
Among disease indication, late stage segment is estimated to hold a dominant position in the U.S. degenerative disc disease treatment market. Disc degeneration can cause or augment other conditions such as spinal stenosis, the narrowing of the spaces in the spine, spondylolisthesis, the slippage of one disc over another or osteoarthritis of the spine. Conservative therapies such as physical therapy, pain relievers, and others may alleviate some of the symptoms of degenerative disc disease. However, if those treatments fail, surgery may be the last option of treatment for late stage degenerative disc disease.
 
Key players operating in the U.S. degenerative disc disease treatment market include AnGes Inc., Ankasa Regenerative Therapeutics Inc., BIOPHARM GMBH, BioRestorative Therapies Inc., Biosplice Therapeutics Inc., Bone Therapeutics SA, Cerapedics Inc., CO.DON, Creative Medical Technology Holdings Inc., DiscGenics Inc., Eli Lilly and Company, Ferring Pharmaceuticals, FibroGenesis, Geistlich Pharma AG, Harbor View Medical Services PC, Intralink-Spine Inc., Isto Biologics, Johnson & Johnson, Kolon TissueGene Inc., Kunovus, Lineage Cell Therapeutics Inc., Mesoblast, NC Biomatrix BV, Notogen Inc., Pfizer Inc., R3 Stem Cell, Smith & Nephew, Spine BioPharma, Stayble Therapeutics AB, US Stem Cell Inc., and VIVEX Biologics Inc.